Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomesInterim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States
Frutos A, Price A, Harker E, Reeves E, Ahmad H, Murugan V, Martin E, House S, Saade E, Zimmerman R, Gaglani M, Wernli K, Walter E, Michaels M, Staat M, Weinberg G, Selvarangan R, Boom J, Klein E, Halasa N, Ginde A, Gibbs K, Zhu Y, Self W, Tartof S, Klein N, Dascomb K, DeSilva M, Weber Z, Yang D, Ball S, Surie D, DeCuir J, Dawood F, Moline H, Toepfer A, Clopper B, Link-Gelles R, Payne A, Chung J, Flannery B, Lewis N, Olson S, Adams K, Tenforde M, Garg S, Grohskopf L, Reed C, Ellington S, Collaborators C, Collaborators C, Lauring A, Arndorfer J, Bride D, Peltan I, Mohr N, Hager D, Prekker M, Mohamed A, Johnson N, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughan I, Mosier J, Safdar B, Harris E, Chappell J, Stewart L, Swan S, Piedra P, Sahni L, Englund J, Zerr D, Hickey R, Williams J, Rohlfs C, Schlaudecker E, Dosdos D, Moffatt M, Schuster J, Weltmer K, Szilagyi P, Curley T, Mills J, Faryar K, Salata R, Geffel K, Nowalk M, Murthy K, Rose S, Smith M, Wickersham B, Williamson B, Bontrager N, Williams O, Kramer J, Nordstrom L, Monto A, Vaughn I, Dickerson M, McLean C, Noble E, Ray C, Sumner K, Essien I, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Bezi C, Contreras R, Davis G, Lewin B, Mahale P, Patrick R, Qian L, Rayens E, Reyes I, Ryan D, Salas S, Sy L, Yeh M, Zeng X, Fireman B, Goddard K, Hansen J, Jacobson K, Timbol J, Zerbo O, Dunne M, Zhuang Y. Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States. MMWR Morbidity And Mortality Weekly Report 2024, 73: 168-174. PMID: 38421935, PMCID: PMC10907036, DOI: 10.15585/mmwr.mm7308a3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultCase-Control StudiesChildHumansInfluenza VaccinesInfluenza, HumanSeasonsVaccine EfficacyConceptsVaccine effectivenessInfluenza vaccineInfluenza virus infectionInfluenza-associated hospitalizationsAnnual influenza vaccinationSeasonal influenza vaccineTest-negative case-control study designCase-control study designOutpatient visitsInfluenza VEInfluenza BInfluenza seasonInfluenza APediatric patientsInfluenzaVirus infectionOutpatient settingMonthsVaccinePatientsStudy designHospitalAdultsVisitsUnited States